15-min delayed · Aug 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Cellectar Biosciences Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 294% above the current $2.54. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.53 next quarter toward $-1.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Cellectar Biosciences Inc.
As of Aug, 2 of 2 firms rate CLRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLRB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.53
Range $-0.68 – $-0.43 · 4 analysts · +0% YoY
Next period, 4 analysts expect Cellectar Biosciences Inc to earn $-0.53 a share (range $-0.68 – $-0.43), versus $-0.53 a year earlier. Full-year consensus is $-2.43, growing to $-1.92 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $7.6M next year.
Top analysts covering Cellectar Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLRB.
#1
Jeff Jones
Oppenheimer · Rank #231
Hold
No targeton CLRB
Overall win rate
33%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Buy
$10.00+294.5% to target
Overall win rate
33%
+ Follow
#3
Jonathan Aschoff
Roth MKM · Rank #444
Buy
$11.00+333.9% to target
Overall win rate
28%
+ Follow
#4
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$10.00+294.5% to target
Coverage
—
+ Follow
CLRB stock forecast FAQ
What is CLRB's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Cellectar Biosciences Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is CLRB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CLRB?+
2 analysts have an active rating on Cellectar Biosciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLRB?+
Among analysts who currently cover CLRB, Jeff Jones of Oppenheimer has the strongest overall Quantellect track record (Rank #231). Their current call is Hold.
What is Cellectar Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.53 per share (range $-0.68 – $-0.43) across 4 analysts. Full-year EPS is projected at $-2.43, rising to $-1.92 the following year.
How much revenue is Cellectar Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.6M next year.
Have analysts been upgrading or downgrading CLRB lately?+
As of Aug, 2 of 2 firms rate CLRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLRB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
